Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Comprehensive Analysis of Lung Cancer Metastasis: Sites, Rates, Survival, and Risk Factors-A Systematic Review and Meta-Analysis.The clinical respiratory journal · 2025
   Pooled it
2. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.Neuro-oncology · 2021
   Trial
3. EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.BMC cancer · 2026
   Article
4. Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.Cancer science · 2022
   Article
5. Treatment preferences for epidermal growth factor receptor mutation-positive non-small cell lung cancer with brain metastasis: a large-scale survey from Chinese oncologists.Annals of translational medicine · 2022
   Article
6. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.Thoracic cancer · 2021
   Observational
7. Complete Remission of Multiple Brain Metastases in a Patient withCase reports in oncological medicine · 2020
   Article
8. Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases.Journal of Cancer · 2019
   Article
9. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.Frontiers in oncology · 2018
   Article
10. The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.Neuro-oncology advances
    Article
11. Therapeutic Outcomes of Osimertinib in EGFR - Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital.Cancer control : journal of the Moffitt Cancer Center
    Article

Corrections and comments

• Comment on
  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as